tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

TriSalus Life Sciences Grants CFO Stock Options

Story Highlights
TriSalus Life Sciences Grants CFO Stock Options

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

TriSalus Life Sciences ( (TLSI) ) has provided an announcement.

On August 25, 2025, TriSalus Life Sciences, Inc. approved an increase in the annual compensation of their Chief Financial Officer, Mr. David Patience, from $450,000 to $550,000. Additionally, on August 28, 2025, the company granted Mr. Patience stock options to purchase 249,899 shares of common stock, contingent upon the company achieving or exceeding $75 million in revenue over a twelve-month period before the end of 2027.

The most recent analyst rating on (TLSI) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on TriSalus Life Sciences stock, see the TLSI Stock Forecast page.

Spark’s Take on TLSI Stock

According to Spark, TipRanks’ AI Analyst, TLSI is a Neutral.

The overall stock score is primarily influenced by financial performance challenges, including negative equity and cash flow issues. While there are positive aspects such as revenue growth and strategic corporate events, the financial instability and unattractive valuation weigh heavily on the score.

To see Spark’s full report on TLSI stock, click here.

More about TriSalus Life Sciences

Average Trading Volume: 101,834

Technical Sentiment Signal: Sell

Current Market Cap: $254.8M

For a thorough assessment of TLSI stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1